

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was the approximate reduction of risk of progression or death observed with first-line nivolumab in combination with ipilimumab versus standard chemotherapy in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (mCRC) in the Phase III Checkmate 8HW trial?**
 - a. 19%
 - b. 39%
 - c. 59%
 - d. 79%
- 2. Which of the following best describes the efficacy of trastuzumab deruxtecan by HER2 status in patients with advanced HER2-expressing CRC in the Phase II DESTINY-CRC02 study?**
 - a. Objective response rate (ORR) was equivalent in IHC 3+ and IHC 2+/ISH-positive disease
 - b. ORR was greatest in IHC 3+ disease
 - c. ORR was greatest in IHC 2+/ISH-positive disease
- 3. Which of the following best describes results with sotorasib and panitumumab in patients with previously treated, KRAS G12C-mutated mCRC in the Phase III CodeBreaK 300 study?**
 - a. No improvement in overall survival (OS) or progression-free survival (PFS)
 - b. Significant improvement in PFS and no improvement in OS
 - c. Significant improvement in PFS and trend toward improved OS
 - d. Significant improvement in both PFS and OS
- 4. Approximately what fraction of rectal cancers are considered MSI-H?**
 - a. Less than 1%
 - b. 5% to 10%
 - c. 2% to 25%
 - d. Greater than 40%
- 5. Major pathologic responses were observed in approximately what percent of patients who received neoadjuvant nivolumab/ipilimumab for locally advanced mismatch repair-deficient colon cancer in the Phase II NICHE-2 trial?**
 - a. 25%
 - b. 50%
 - c. 75%
 - d. Greater than 90%